JMI Syringes & Medical Devices Ltd

JMI Syringes & Medical Devices Ltd maintains a strong liquidity position, with a current ratio of 5.12, indicating that it holds significantly more current assets than current liabilities. However, the company's free cash flow is negative at -163,999,180 BDT, which suggests that capital expenditures are outpacing operating cash flow. The company's cash and equivalents amount to 51,709,180 BDT, but this is offset by long-term debt of 132,842,240 BDT, resulting in a net cash position that is negative after subtracting total debt.

Profitability metrics are concerning, with a return on equity of -7.03% and a return on assets of -6.09%, both significantly below the industry median for medical equipment and supplies. The company reported a net loss of 182,495,630 BDT, despite a gross profit of 44,960,270 BDT, indicating high operating and non-operating expenses.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks.

Looking ahead, the company's revenue is expected to remain under pressure, with no clear growth trajectory evident from the current financial data. The operating cash flow of 65,723,550 BDT is insufficient to cover capital expenditures of 44,436,420 BDT, which may hinder long-term growth and operational flexibility.

The risk assessment indicates a medium liquidity risk, primarily due to the negative free cash flow and the net cash position being negative after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding.

Recent filings and transcripts do not provide additional insights into the company's strategic direction or operational performance. The company's financial health remains a concern, with a net loss and negative returns on equity and assets.

Net income surged 125.9% year-over-year to BDT 38.9 million, marking a significant recovery from the previous fiscal loss.

Operating income jumped 87.8% year-over-year to BDT 139.9 million, demonstrating strong improvement in core operational profitability.

Free cash flow turned positive to BDT 96.9 million, reversing a previous deficit and indicating improved cash generation.

The company maintains a low debt-to-equity ratio of 0.05, suggesting a conservative capital structure with limited leverage risk.

Dilution risk is assessed as low, providing reassurance to existing shareholders regarding potential equity value erosion.

Revenue declined at a 2.4% CAGR over four years, indicating a persistent inability to grow the top line.

The company faces high credit risk, which could impair its ability to secure financing or maintain supplier relationships.